Cancer patients having COVID-19 in Primorsky region: Morbidity and mortality
https://doi.org/10.34215/1609-1175-2020-4-5-9
Abstract
In the end of the year 2019 there was an outbreak of the new coronavirus infection with the epicenter in China, Wuhan (Hubei province). On 11th of February WHO defined an official name of the infection generated by new coronavirus – COVID-19 (COronaVIrus Disease 2019). On the 11th of February the International Committee on Virus Taxonomy assigned the name to the causative agent – SARS-CoV-2. The emergence of the COVID-19 set the task to the medical specialists connected with the fast diagnostics and providing medical treatment to the patients. Currently the intensive study of the clinical and epidemiological peculiarities of the disease, the development of new ways of prevention and treatment is the ongoing process. In this article the results of the morbidity and death rates connected with COVID-19 of the patients having cancer in Primorskiy region from 31st of March to 31st of August 2020 are introduced.
About the Authors
A. V. Fateeva
Primorskiy Regional Oncological Dispensary
Russian Federation
Russian Federation
MD, Primorskiy Regional Oncological Dispensary,
59 Russkaya St., Vladivostok, 690105
L. I. Gurina
Primorskiy Regional Oncological Dispensary;
Pacific State Medical University
Russian Federation
Russian Federation
MD, PhD, deputy chief physician,
59 Russkaya St., Vladivostok, 690105
References
1. Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of unknown aetiology in Wuhan, China: Potential for international spread via commercial air travel. J Travel Med. 2020;27. doi: 10.1093/jtm/taaa008
2. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020. doi: 10.1002/jmv.25678
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–13.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
5. Chavez S, Long B, Koyfman A, Liang SY. Coronavirus disease (COVID-19): A primer for emergency physicians. Am J Emerg Med. 2020. doi: 10.1016/j.ajem.2020.03.036.
6. WHO clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. 2020. URL: file:///C:/Users/79025/Downloads/WHO-2019-nCoV-clinical-2020.5-eng.pdf (Accessed: 6 October 2020).
7. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020.21(3):335–7.
8. Profilaktika, diagnostika I lechenie novoij coronovirusnoij infecii (COVID-19). Versia 8 (03.09.2020). Glava 2 (In Russ). URL: https://static0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8 (Accessed: 6 October 2020).
9. World Health Organization. Weekly Epidemiological Update Coronavirus disease 2019 (COVID-19), 5.10.2020. URL:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201005-weekly-epi-update-8 (Accessed: 6 October 2020).
10. Operativnie dannie po sostoianiu na 6 oct. 2020 (In Russ). URL: Стопкоронавирус.рф (Accessed: 6 October 2020).
11. Karta coronavirusa online. Primorskij kray. 6 October 2020 (In Russ). URL: Сoronavirus-control.ru/coronavirus-primorskijkraj (Accessed: 6 October 2020).
12. Assaad S, Avrillon V, Fournier M-L, Mastroianni B, Russias B, Swalduz A, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. Eur J Cancer. 2020;135:251–9.
13. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, et al. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Sign Transduct Target Ther. 2020;5(1):33.
14. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: The perspectives on immune responses. Cell Death Differ. 2020.27:1451–4.
15. Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS. COVID-19 and cancer: A comprehensive review. Curr Oncol Rep. 2020;22:53. doi: 10.1007/s11912-020-00934-7
16. Novosti Vladivostoka in Vl.ru po sostoianiu 31.08.2020 (In Russ). URL: https://www.newsvl.ru/covid19/2020/08/31/192676 (Accessed: 6 October 2020).
17. Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: Scholarly review. Br J Dermatol. 2017;177(2):359–72.
18. Kaprin AD, Starinsky VV, Petrova GV, eds. The situation of oncological assistance to the population of Russia in 2018. Moscow; 2019 (In Russ).
19. Merabishvili VM. Malignant tumors in the North-West Federal Region of Russia (morbidity, mortality, index accuracy, survival). Express-information. Fifth Issue. Saint Petersburg; 2020:236 (In Russ).
Review
For citations:
Fateeva A.V., Gurina L.I. Cancer patients having COVID-19 in Primorsky region: Morbidity and mortality. Pacific Medical Journal. 2020;(4):5-9. (In Russ.) https://doi.org/10.34215/1609-1175-2020-4-5-9
Views:
826
Email this article 